Birth Defects Not Up Significantly With Anti-TNFs in Pregnancy

This article originally appeared here.
Share this content:
Birth Defects Not Up Significantly With Anti-TNFs in Pregnancy
Birth Defects Not Up Significantly With Anti-TNFs in Pregnancy

MONDAY, Feb. 22, 2016 (HealthDay News) -- Birth defects are not significantly more prevalent among women receiving anti-tumor necrosis factor (TNF) agents during pregnancy, according to a study published in the February issue of Clinical Gastroenterology and Hepatology.

Gabriella Bröms, M.D., from the Karolinska Institutet in Stockholm, and colleagues collected data on 1,272,424 live-born infants identified from the Danish and Swedish population-based health registers. They examined the prevalence of birth defects among infants born to women with chronic inflammatory disease (683 treated with and 21,549 without anti-TNF agents during early pregnancy) and in the general population.

The researchers found that the prevalence of birth defects was higher among infants born to women with chronic inflammatory disease than in the general population (4.8 versus 4.2 percent), irrespective of anti-TNF treatment status. Birth defects occurred in 6.3 percent of infants born to women who received anti-TNF treatment versus 4.7 percent of infants born to women with chronic inflammatory disease who received no treatment. In women receiving anti-TNF treatment, the odds ratios were 1.32 (95 percent confidence interval [CI], 0.93 to 1.82) for any defect; 1.60 (95 percent CI, 0.93 to 2.58) for a cardiovascular defect; and 2.22 (95 percent CI, 0.86 to 4.71) for a urinary defect.

"Women who received anti-TNF agents during pregnancy had a slightly (but not significantly) higher risk of having children with birth defects," the authors write.

The authors' institutions have received financial support from pharmaceutical companies. The study was developed independently from a post-authorization safety study commissioned via Janssen Biotech.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »